{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:43:36Z","timestamp":1770756216349,"version":"3.50.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jiac.2025.102724","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T15:30:00Z","timestamp":1746545400000},"page":"102724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of the efficacy of step-down therapy with oral minocycline for complicated pyelonephritis caused by extended-spectrum \u03b2-lactamase-producing enterobacterales: A retrospective cohort study"],"prefix":"10.1016","volume":"31","author":[{"given":"Ryota","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6262-1150","authenticated-orcid":false,"given":"Takashi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0827-2102","authenticated-orcid":false,"given":"Yuta","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2025.102724_bib1","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.14822.1","article-title":"Treatment of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now?","volume":"7","author":"Pana","year":"2018","journal-title":"F1000Research"},{"key":"10.1016\/j.jiac.2025.102724_bib2","first-page":"935","article-title":"Emergence of extended-spectrum \u03b2-lactamase (ESBL) and\/or carbapenemase producing Enterobacteriaceae (CPE) and their antimicrobial resistance","volume":"120","author":"Kore\u0148","year":"2019","journal-title":"Bratisl Lek Listy"},{"key":"10.1016\/j.jiac.2025.102724_bib3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00003495-200363040-00002","article-title":"Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: Considerations for diagnosis, prevention and drug treatment","volume":"63","author":"Rupp","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.jiac.2025.102724_bib4","first-page":"181","article-title":"Current trends in antimicrobial resistance of Escherichia coli","volume":"416","author":"Paitan","year":"2018","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.jiac.2025.102724_bib5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102724_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00079-17","article-title":"Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC\u2212, and carbapenemase-producing Enterobacteriaceae","volume":"31","author":"Rodr\u00edguez-Ba\u00f1o","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jiac.2025.102724_bib7","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/ciy525","article-title":"Rapid and extensive expansion in the United States of a new multidrug-resistant Escherichia coli clonal group, sequence Type 1193","volume":"68","author":"Tchesnokova","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102724_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220265","article-title":"The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017","volume":"14","author":"Critchley","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2025.102724_bib9","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jiac.2016.11.003","article-title":"The efficacy of faropenem for patients with acute cystitis caused by extended spectrum \u03b2-lactamase producing Escherichia coli","volume":"23","author":"Fujino","year":"2017","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102724_bib10","doi-asserted-by":"crossref","first-page":"dlac125","DOI":"10.1093\/jacamr\/dlac125","article-title":"A systematic scoping review of faropenem and other oral penems: treatment of Enterobacterales infections, development of resistance and cross-resistance to carbapenems","volume":"4","author":"Gandra","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.jiac.2025.102724_bib11","series-title":"Performance standards for antimicrobial susceptibility testing. M100-Ed33","year":"2023"},{"key":"10.1016\/j.jiac.2025.102724_bib12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2025.102724_bib13","series-title":"R: a language and environment for statistical computing","year":"2024"},{"key":"10.1016\/j.jiac.2025.102724_bib15","first-page":"855","article-title":"Impact of printed antimicrobial stewardship recommendations on early intravenous to oral antibiotics switch practice in district hospitals","volume":"16","author":"Sze","year":"2018","journal-title":"Pharm Pract"},{"key":"10.1016\/j.jiac.2025.102724_bib16","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.2460\/ajvr.71.9.1062","article-title":"Pharmacokinetics and tissue distribution of minocycline hydrochloride in horses","volume":"71","author":"Nagata","year":"2010","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.jiac.2025.102724_bib17","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0924-8579(02)00105-X","article-title":"Correlation between pharmacokinetic\/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection","volume":"19","author":"Frimodt-M\u00f8ller","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2025.102724_bib18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/AAC.44.1.156-163.2000","article-title":"Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies","volume":"44","author":"Hvidberg","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102724_bib19","first-page":"865","article-title":"Minocycline for urinary tract infection","volume":"18","author":"Tado","year":"1972","journal-title":"Acta Urol Jpn"},{"key":"10.1016\/j.jiac.2025.102724_bib20","first-page":"501","article-title":"[Application of minocycline to urinary tract infections]","volume":"22","author":"Ishigami","year":"1969","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.jiac.2025.102724_bib21","first-page":"294","article-title":"Minocycline HCL in urinary tract infection - a clinical trial","volume":"33","author":"Gardezi","year":"1983","journal-title":"J Pakistan Med Assoc"},{"key":"10.1016\/j.jiac.2025.102724_bib22","first-page":"47","article-title":"[Male genito-urinary tract infection caused by Chlamydia trachomatis and seminal characteristics: use of minocycline]","volume":"62","author":"Lombardo","year":"1990","journal-title":"Archivio Ital. Urol, Nefrol, Androl"},{"issue":"2434","key":"10.1016\/j.jiac.2025.102724_bib23","article-title":"In vitro efficacy of minocycline on clinical Gram-negative bacterial isolates","volume":"10","author":"Saleh","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2025.102724_bib24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40121-017-0153-2","article-title":"Minocycline for the treatment of multidrug and extensively drug-resistant A. baumannii: a review","volume":"6","author":"Lashinsky","year":"2017","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiac.2025.102724_bib25","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.bbagen.2012.01.011","article-title":"Minocycline ameliorates LPS-induced inflammation in human monocytes by novel mechanisms including LOX-1, Nur77 and LITAF inhibition","volume":"1820","author":"Pang","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jiac.2025.102724_bib26","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/cid\/cix833","article-title":"Low risk of primary Clostridium difficile infection with tetracyclines: a systematic review and metaanalysis","volume":"66","author":"Tariq","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102724_bib27","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1542\/peds.2015-0409","article-title":"Risk factors for recurrent urinary tract infection and renal scarring","volume":"136","author":"Keren","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.jiac.2025.102724_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz216","article-title":"No clinical benefit to treating male urinary tract infection longer than seven days: an outpatient database study","volume":"6","author":"Germanos","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2025.102724_bib29","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1086\/652657","article-title":"Risk factors for bacteremia with uropathogen not cultured from urine in adults with febrile urinary tract infection","volume":"50","author":"van Nieuwkoop","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102724_bib30","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/cid\/ciy1054","article-title":"Seven versus 14 days of antibiotic therapy for uncomplicated Gram-negative bacteremia: a noninferiority randomized controlled trial","volume":"69","author":"Yahav","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102724_bib31","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1001\/jama.2020.6348","article-title":"Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated Gram-negative bacteremia: a randomized clinical trial","volume":"323","author":"von Dach","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jiac.2025.102724_bib32","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cmi.2021.09.001","article-title":"Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial","volume":"28","author":"Molina","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2025.102724_bib33","first-page":"539","article-title":"Antimicrobial treatment duration and outcomes in patients with bacteremia caused by extended-spectrum \u03b2 -lactamase-producing Gram-negative bacteria: a single-center retrospective study","volume":"68","author":"Nakakura","year":"2020","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2025.102724_bib34","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/phar.2024","article-title":"Intravenous-only or intravenous transitioned to oral antimicrobials for Enterobacteriaceae-associated bacteremic urinary tract infection","volume":"37","author":"Rieger","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2025.102724_bib35","first-page":"359","article-title":"Efficacy of switching from initial intravenous cefmetazole treatment to oral antibiotic treatment in patients with bloodstream infection caused by ESBL-producing Escherichia coli","volume":"70","author":"Takahashi","year":"2022","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2025.102724_bib36","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jiac.2021.03.012","article-title":"Nationwide surveillance of bacterial pathogens isolated from patients with acute uncomplicated cystitis in 2018: conducted by the Japanese Research Group for Urinary Tract Infections (JRGU)","volume":"27","author":"Wada","year":"2021","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102724_bib37","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jiac.2024.03.024","article-title":"Fourth national Japanese antimicrobial susceptibility pattern surveillance program: bacterial isolates from patients with complicated urinary tract infections","volume":"30","author":"Kobayashi","year":"2024","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102724_bib38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.14740\/jocmr3928","article-title":"Change in the antimicrobial resistance profile of extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"11","author":"Miyazaki","year":"2019","journal-title":"J Clin Med Res"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25001217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25001217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T07:03:07Z","timestamp":1749711787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X25001217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1341321X25001217"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102724","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the efficacy of step-down therapy with oral minocycline for complicated pyelonephritis caused by extended-spectrum \u03b2-lactamase-producing enterobacterales: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102724","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102724"}}